Last 7 days
-4.1%
Last 30 days
-15.6%
Last 90 days
-15.8%
Trailing 12 Months
-43.5%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 125.3B | 26.3B | -2.75% | 3.76% | 19.12 | 4.76 | 1.32% | 11.18% |
GILD | 99.6B | 27.3B | -8.96% | 41.01% | 21.68 | 3.65 | -0.09% | -26.23% |
MRNA | 58.4B | 19.3B | -12.76% | 1.00% | 6.99 | 3.03 | 4.29% | -31.47% |
BIIB | 38.3B | 10.2B | -9.67% | 32.94% | 12.57 | 3.76 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.1B | 1.5B | -9.09% | 3.35% | 58.87 | 6.11 | 31.34% | 72.43% |
DNLI | 3.2B | 108.5M | -21.10% | -19.55% | -9.78 | 29.38 | 122.90% | -12.19% |
BEAM | 2.5B | 60.9M | -18.47% | -36.46% | -8.76 | 41.55 | 17.51% | 22.00% |
BBIO | 2.1B | 107.9M | 22.95% | 67.45% | -4.29 | 19.27 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -14.86% | -46.41% | -4.63 | 11.04 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -22.18% | 24.65% | -7.11 | 158.97 | 131.81% | -45.39% |
FATE | 541.9M | 96.3M | -12.99% | -82.24% | -1.92 | 5.63 | 72.44% | -32.79% |
NVAX | 513.7M | 2.0B | -39.67% | -92.01% | -0.78 | 0.26 | 72.89% | 62.27% |
SGMO | 355.3M | 111.3M | -30.55% | -58.78% | -1.85 | 3.19 | 0.54% | -7.86% |
VXRT | 101.4M | 159.0K | -16.47% | -82.96% | -0.97 | 637.62 | -86.46% | -64.56% |
IBIO | 25.1M | - | 94.03% | -77.12% | -0.31 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -23.5% | 20.00 | 26.00 | 32.00 | 29.00 | 26.00 |
Operating Expenses | 6.9% | 246 | 230 | 218 | 213 | 219 |
S&GA Expenses | 2.1% | 71.00 | 69.00 | 69.00 | 74.00 | 76.00 |
R&D Expenses | 9.0% | 175 | 161 | 148 | 139 | 143 |
Net Income | -9.6% | -220 | -201 | -184 | -186 | -192 |
Net Income Margin | -43.2% | -11.18* | -7.81* | -5.80* | -6.50* | - |
Free Cahsflow | -3.1% | -181 | -176 | -170 | -173 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -3.1% | 514 | 531 | 581 | 623 | 677 |
Current Assets | -16.4% | 357 | 427 | 461 | 497 | 507 |
Cash Equivalents | -32.8% | 142 | 211 | 169 | 211 | 204 |
Net PPE | 0.5% | 16.00 | 15.00 | 16.00 | 17.00 | 17.00 |
Liabilities | 32.1% | 154 | 116 | 115 | 110 | 124 |
Current Liabilities | 42.1% | 60.00 | 42.00 | 36.00 | 37.00 | 47.00 |
Shareholder's Equity | -13.0% | 361 | 415 | 465 | 513 | 554 |
Retained Earnings | -7.8% | -1,078 | -1,000 | -961 | -908 | -857 |
Additional Paid-In Capital | 0.4% | 1,442 | 1,436 | 1,430 | 1,423 | 1,412 |
Shares Outstanding | 0.1% | 69.00 | 69.00 | 69.00 | 69.00 | 68.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -4.5% | -177,349 | -169,658 | -162,439 | -163,551 | -163,803 |
Share Based Compensation | -7.3% | 29,294 | 31,587 | 35,718 | 42,626 | 43,399 |
Cashflow From Investing | -3.9% | 114,068 | 118,756 | -10,132 | -1,339 | -54,466 |
Cashflow From Financing | -25.4% | 1,284 | 1,722 | 4,138 | 20,853 | 282,106 |
100%
88.8%
78.1%
Y-axis is the maximum loss one would have experienced if Editas Medicine was unfortunately bought at previous high price.
-17.0%
-26.0%
-24.2%
FIve years rolling returns for Editas Medicine.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | sold off | -100 | -132,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -9.33 | -79,000 | 152,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -89,827 | 236,173 | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | reduced | -96.22 | -1,158,400 | 32,597 | -% |
2023-02-24 | NATIXIS | new | - | 23,647 | 23,647 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -24,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -99.68 | -2,991 | 9.00 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | added | 5.63 | -671 | 4,329 | -% |
2023-02-16 | GHP Investment Advisors, Inc. | unchanged | - | -226 | 1,774 | -% |
2023-02-15 | Financial Advocates Investment Management | sold off | -100 | -943,000 | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 10.00% | 6,873,123 | SC 13G/A | |
Feb 03, 2023 | state street corp | 13.41% | 9,222,236 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 10.7% | 7,338,742 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 10.7% | 7,338,742 | SC 13G/A | |
Jul 11, 2022 | state street corp | 11.48% | 7,879,890 | SC 13G/A | |
Mar 09, 2022 | vanguard group inc | 10.69% | 7,328,042 | SC 13G/A | |
Feb 14, 2022 | nikko asset management americas, inc. | 3.91% | 2,675,235 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 9.76% | 6,673,897 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 6.17% | 4,218,302 | SC 13G/A | |
Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 3.91% | 2,675,235 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 1.28 -84.92% | 1.31 -84.57% | 1.40 -83.51% | 1.55 -81.74% | 1.88 -77.86% |
Current Inflation | 1.28 -84.92% | 1.31 -84.57% | 1.38 -83.75% | 1.52 -82.10% | 1.81 -78.68% |
Very High Inflation | 1.27 -85.04% | 1.30 -84.69% | 1.37 -83.86% | 1.48 -82.57% | 1.72 -79.74% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 14, 2023 | 8-K | Current Report | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 10-K | Annual Report | |
Feb 22, 2023 | 8-K | Current Report | |
Feb 22, 2023 | S-8 | Employee Benefits Plan | |
Feb 15, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-03 | Eaton Bruce | sold | -897 | 8.89 | -101 | evp, cbo and cto |
2023-03-03 | ROBERTSON MICHELLE | sold | -1,635 | 8.89 | -184 | evp, chief financial officer |
2023-03-02 | Mei Baisong | acquired | - | - | 18,000 | svp, chief medical officer |
2023-03-02 | O'Neill Gilmore Neil | acquired | - | - | 50,000 | ceo |
2023-03-02 | ROBERTSON MICHELLE | acquired | - | - | 31,500 | evp, chief financial officer |
2023-03-02 | Eaton Bruce | acquired | - | - | 16,700 | evp, cbo and cto |
2023-02-13 | ROBERTSON MICHELLE | sold | -41,435 | 9.6653 | -4,287 | evp, chief financial officer |
2023-02-13 | Eaton Bruce | sold | -31,963 | 9.6653 | -3,307 | evp, cbo and cto |
2023-02-13 | Shearman Mark S | sold | -26,966 | 9.6653 | -2,790 | evp, chief scientific officer |
2023-02-07 | Eaton Bruce | sold | -3,840 | 11.1 | -346 | evp, cbo and cto |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Consolidated Statements of Operations | |||
Collaboration and other research and development revenues | $ 19,712 | $ 25,544 | $ 90,732 |
Revenue type | us-gaap:ServiceMember | us-gaap:ServiceMember | us-gaap:ServiceMember |
Operating expenses: | |||
Research and development | $ 174,958 | $ 142,507 | $ 157,996 |
General and administrative | 70,704 | 76,183 | 67,576 |
Total operating expenses | 245,662 | 218,690 | 225,572 |
Operating loss | (225,950) | (193,146) | (134,840) |
Other income, net: | |||
Other income (expense), net | 1,293 | (1,698) | 16,259 |
Interest income, net | 4,225 | 2,342 | 2,605 |
Total other income, net | 5,518 | 644 | 18,864 |
Net loss | (220,432) | (192,502) | (115,976) |
Net loss, basic | (220,432) | (192,502) | (115,976) |
Net loss, diluted | $ (220,432) | $ (192,502) | $ (115,976) |
Net loss per share, basic (in dollars per share) | $ (3.21) | $ (2.85) | $ (1.98) |
Net loss per share, diluted (in dollars per share) | $ (3.21) | $ (2.85) | $ (1.98) |
Weighted-average common shares outstanding, basic (in shares) | 68,664,822 | 67,619,388 | 58,609,389 |
Weighted-average common shares outstanding, diluted (in shares) | 68,664,822 | 67,619,388 | 58,609,389 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 141,522 | $ 203,519 |
Marketable securities | 202,752 | 296,326 |
Accounts receivable | 5,145 | 267 |
Prepaid expenses and other current assets | 7,335 | 7,198 |
Total current assets | 356,754 | 507,310 |
Marketable securities | 93,097 | 120,071 |
Property and equipment, net | 15,569 | 17,118 |
Right-of-use assets | 43,648 | 26,173 |
Restricted cash and other non-current assets | 5,253 | 6,811 |
Total assets | 514,321 | 677,483 |
Current liabilities: | ||
Accounts payable | 9,511 | 5,050 |
Accrued expenses | 31,296 | 20,192 |
Deferred revenue, current | 8,221 | 11,333 |
Operating lease liabilities | 11,082 | 10,309 |
Total current liabilities | 60,110 | 46,884 |
Operating lease liabilities, net of current portion | 32,864 | 16,069 |
Deferred revenue, net of current portion | 60,667 | 60,888 |
Total liabilities | 153,641 | 123,841 |
Stockholders' equity | ||
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding | ||
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,847,382 and 68,489,257 shares issued, and 68,847,382 and 68,435,257 shares outstanding at December 31, 2022 and December 31, 2021, respectively | 7 | 7 |
Additional paid-in capital | 1,442,405 | 1,411,827 |
Accumulated other comprehensive loss | (3,601) | (493) |
Accumulated deficit | (1,078,131) | (857,699) |
Total stockholders' equity | 360,680 | 553,642 |
Total liabilities and stockholders' equity | $ 514,321 | $ 677,483 |